162.00
Iqvia Holdings Inc stock is traded at $162.00, with a volume of 2.00M.
It is down -3.51% in the last 24 hours and down -0.17% over the past month.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
See More
Previous Close:
$167.90
Open:
$166.18
24h Volume:
2.00M
Relative Volume:
1.12
Market Cap:
$27.04B
Revenue:
$16.63B
Net Income/Loss:
$1.39B
P/E Ratio:
20.08
EPS:
8.0674
Net Cash Flow:
$2.12B
1W Performance:
-6.46%
1M Performance:
-0.17%
6M Performance:
-30.11%
1Y Performance:
+18.25%
Iqvia Holdings Inc Stock (IQV) Company Profile
Name
Iqvia Holdings Inc
Sector
Industry
Phone
919-998-2000
Address
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
IQV
Iqvia Holdings Inc
|
162.00 | 28.02B | 16.63B | 1.39B | 2.12B | 8.0674 |
|
TMO
Thermo Fisher Scientific Inc
|
448.18 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
172.81 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
557.21 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
|
WAT
Waters Corp
|
338.64 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
|
A
Agilent Technologies Inc
|
115.08 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Iqvia Holdings Inc Stock (IQV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Mar-06-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-03-26 | Initiated | RBC Capital Mkts | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Nov-13-25 | Initiated | BMO Capital Markets | Outperform |
| Nov-03-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-29-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-09-25 | Upgrade | HSBC Securities | Hold → Buy |
| Sep-09-25 | Upgrade | Jefferies | Hold → Buy |
| Apr-25-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-03-25 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-20-24 | Initiated | Stephens | Overweight |
| Oct-14-24 | Initiated | Redburn Atlantic | Buy |
| Sep-04-24 | Initiated | RBC Capital Mkts | Outperform |
| Jul-24-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-06-24 | Initiated | Goldman | Buy |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Feb-15-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-13-24 | Initiated | BTIG Research | Buy |
| Nov-02-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Mar-17-23 | Initiated | Truist | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Nov-17-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-15-22 | Initiated | SVB Leerink | Outperform |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-29-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-16-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Mar-08-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jul-07-20 | Initiated | Stephens | Equal-Weight |
| Mar-02-20 | Initiated | Deutsche Bank | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Overweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Upgrade | CFRA | Sell → Hold |
| Nov-14-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-21-19 | Upgrade | Mizuho | Neutral → Buy |
| May-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-18-19 | Upgrade | Jefferies | Hold → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Oct-02-18 | Reiterated | Robert W. Baird | Outperform |
| Jul-25-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-25-18 | Reiterated | Stifel | Buy |
| Jul-03-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Apr-13-18 | Upgrade | Goldman | Neutral → Buy |
| Mar-07-18 | Upgrade | SunTrust | Hold → Buy |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
View All
Iqvia Holdings Inc Stock (IQV) Latest News
IQVIA CEO to Speak at Jefferies Global Healthcare Conference 2026 - BioSpace
IQVIA Holdings Inc (IQV) Stock Down 3.5% -- Now Undervalued? GF Score: 86/100 - GuruFocus
IQVIA CEO to Speak at Jefferies Global Healthcare Conference - pharmiweb.com
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Are Wall Street analysts predicting IQVIA Holdings stock will climb or sink? - MSN
JPMorgan Mid Cap Equity Fund's IQVIA Holdings Inc(IQV) Holding History - GuruFocus
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term - Yahoo Finance
What Makes IQVIA Holdings (IQV) an Investment Bet? - Insider Monkey
IQVIA Holdings, Inc. (IQV): Analyst Consensus Reveals 36% Upside Potential for Healthcare Giant - DirectorsTalk Interviews
Liquidity Mapping Around (IQV) Price Events - Stock Traders Daily
IQVIA signals raised 2026 adjusted EPS outlook to $12.65-$12.95 while reaffirming $17.150B-$17.350B revenue - MSN
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Beta Bionics, Inc. (BBNX) and Twist Bioscience (TWST) - The Globe and Mail
IQV News | IQVIA HOLDINGS INC (NYSE:IQV) - ChartMill
IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
IQVIA Holdings Inc stock (US46266C1053): data-driven healthcare group in focus after latest earnings - AD HOC NEWS
Are Wall Street Analysts Predicting IQVIA Holdings Stock Will Climb or Sink? - Barchart.com
IQVIA’s SWOT analysis: healthcare stock faces margin pressures - Investing.com
IQVIA: The Market May Be Missing The AI And Data Story (NYSE:IQV) - Seeking Alpha
Research Alert: CFRA Moderates Rating On Shares Of Iqvia Holdings Inc. To Hold From Buy - Moomoo
IQVIA Holdings stock (US46266C1053): latest earnings highlight data strength and AI ambitions - AD HOC NEWS
IQVIA Signals Confidence with $3.2 Billion Share Repurchase War Chest - BriefGlance
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
IQVIA (IQV) Fell Despite Strong Fundamentals - Insider Monkey
IQVIA Holdings, Inc. (IQV) Stock Analysis: Growth Potential and Analyst Consensus Point to 35% Upside - DirectorsTalk Interviews
Mid-Cap Stocks: IQVIA (IQV) and First Citizens (FCNCA) Sell SignalsNews and Statistics - IndexBox
IQVIA Holdings (IQV) Q1 earnings and revenues beat estimates - MSN
IQVIA Holdings stock (US46266C1053): earnings, data growth and what investors watch now - AD HOC NEWS
Repligen, AdaptHealth, and IQVIA Stocks Trade Down, What You Need To Know - Yahoo Finance
IQVIA Holdings Inc stock (US46266C1053): earnings momentum and AI narrative draw fresh attention - AD HOC NEWS
Catholic Responsible Investments Equity Index Fund's IQVIA Holdings Inc(IQV) Holding History - GuruFocus
Is There Now An Opportunity In IQVIA Holdings Inc. (NYSE:IQV)? - Moomoo
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR) - The Globe and Mail
Will IQVIA's (IQV) AI‑Driven Biosimilar Partnership with Kexing Reshape Its Long‑Term Narrative? - Yahoo Finance
IQVIA’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
IQVIA Holdings earnings preview: What to expect - MSN
BofA Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $245 - Moomoo
IQVIA Holdings stock (US46266C1053): Expands AI-powered biosimilars deal with Kexing Biopharm - AD HOC NEWS
IQVIA Holdings, Inc. Common Stock (NY: IQV - FinancialContent
IQVIA expands collaboration with Kexing Biopharm on biosimilars - Investing.com UK
Why (IQV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
IQVIA expands collaboration with Kexing Biopharm on biosimilars By Investing.com - Investing.com Nigeria
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
AI-powered trials to speed global biosimilar drugs in IQVIA-Kexing pact - Stock Titan
IQVIA Holdings stock (US46266C1053): Global leader in healthcare data analytics - AD HOC NEWS
IQVIA Q1 2026 slides: earnings beat drives guidance raise By Investing.com - Investing.com Nigeria
IQVIA Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges By Investing.com - Investing.com South Africa
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges - Investing.com
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term - Yahoo Finance
IQVIA Holdings | 4: Statement of changes in beneficial ownership of securities-Director GOGGINS COLLEEN A - Moomoo
IQVIA (NYSE: IQV) director granted 171 deferred shares at $178.64 - Stock Titan
Iqvia Holdings Inc Stock (IQV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):